市场调查报告书

何杰金氏淋巴瘤的治疗方法的全球市场:成长率、趋势、预测

Hodgkin Lymphoma Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 546541
出版日期 内容资讯 英文 120 Pages
商品交期: 2-3个工作天内
价格
Back to Top
何杰金氏淋巴瘤的治疗方法的全球市场:成长率、趋势、预测 Hodgkin Lymphoma Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 120 Pages
简介

本报告提供何杰金氏淋巴瘤的各种治疗方法、治疗药的市场相关分析,疾病概要和现在/未来可利用的治疗选择,主要的促进、阻碍因素,市场规模趋势预测 (今后6年份),各领域、各地区的详细趋势,近几年的市场竞争的动向,主要企业简介等调查。

第1章 简介

第2章 分析方法

第3章 摘要整理

第4章 主要考察事项

第5章 市场概要、产业趋势

  • 目前市场方案
  • 市场概要
  • 波特的五力分析

第6章 推动、市场的阻碍要素/机会/课题分析 (DROC分析)

  • 市场的推动要素
  • 市场的阻碍要素
  • 市场机会
  • 主要课题

第7章 全球输卵管癌症市场:各领域

  • 治疗方法的种类
    • 手术
    • 化疗
    • 放射治疗

第8章 全球输卵管癌症市场:各地区的市场规模、占有率预测

  • 北美 (美国,加拿大,墨西哥)
  • 欧洲 (德国,英国,法国,义大利,西班牙、葡萄牙,北欧各国,荷比卢三国等)
  • 亚太地区 (中国,日本,印度,澳洲、纽西兰,韩国等)
  • 中东、非洲 (波灣合作理事会 (GCC) 各国,南非等)
  • 南美 (巴西,阿根廷等)

第9章 竞争环境

  • 企业合并、收购 (M&A) 分析
  • 新产品的销售
  • 协定,产业合作、联盟

第10章 企业简介

  • Amgen Inc.
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Celgene
  • Eli Lilly and Company
  • Roche
  • 其他

第11章 投资机会相关分析师的见解

第12章 市场未来展望

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 55414

Hodgkin's lymphoma is a malignant tumor that develops from cells in the lymphatic system called lymphocytes. The cancer is characterized histologically by the presence of multinucleated giant cells called Reed-Sternberg cells and associated abnormal, smaller mononuclear cells originating from B-lymphocytes in the germinal centers of lymphoid tissue. Global statistics show that the number of new cases of Hodgkin's lymphoma is 2.6 per 100,000 men and women, per year. Unlike most cancers, the chances of Hodgkin's lymphoma do not increase with age; they are found to be high in two age groups, young adults and the elderly. The increase in the number of new cases diagnosed every year is expected to drive the Hodgkin's lymphoma treatment market.

Key Market Trends

Radiotherapy Segment is Expected to Register a Significant Growth over the Forecast Period

Based on Treatment Type, it is segmented into Chemotherapy, Radiotherapy, and Others. Radiotherapy is a well-established technique at destroying Hodgkin's disease cells by using high-energy beams or particles to kill cancer cells and may be delivered from a source outside the body, i.e., external beam radiation or internally, such as brachytherapy. For classical Hodgkin's disease, radiotherapy is often given after chemotherapy, especially when there is a large or bulky tumor mass. According to the American Cancer Society, in 2019, around 8,110 people in the United States were diagnosed with Hodgkin lymphoma. Hence, the rising burden of cancer, along with increasing awareness about hodgkin's lymphoma, the market is expected to grow in the forecast period.

North America Expected to Hold the Largest Share in the Hodgkin Lymphoma Treatment Market

The hodgkin lymphoma treatment market expected to hold the largest share in the North America region. According to the American Cancer Society estimates, in 2019, there were around 1,000 deaths (410 women and 590 men) from Hodgkin's lymphoma in the United States. Hodgkin lymphoma affects both children and adults. It is the most commonly diagnosed cancer in teens aged 15 to 19 years. The increasing number of new cases, developed healthcare infrastructure and advanced treatment options are contributing to the growth of the studied market.

Competitive Landscape

The global players into the hodgkin lymphoma treatment market are Alkem Laboratories, Amneal Pharmaceuticals, Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, Incyte Corp, Merck & Co. Inc., Seattle Genetics, Inc. and Teva Pharmaceutical Industries Ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Hodgkin Lymphoma
    • 4.2.2 Increasing Awareness about Hodgkin Lymphoma
    • 4.2.3 High Unmet Need in Older Patients and Patients with Relapsed or Refractory (R/R) HL
  • 4.3 Market Restraints
    • 4.3.1 Adverse Long-term Side Effects
    • 4.3.2 High Cost of Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment Type
    • 5.1.1 Chemotherapy
    • 5.1.2 Radiotherapy
    • 5.1.3 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alkem Laboratories
    • 6.1.2 Amneal Pharmaceuticals, Inc.
    • 6.1.3 Baxter International Inc.
    • 6.1.4 Biogen Inc.
    • 6.1.5 Bristol-Myers Squibb Company
    • 6.1.6 F Hoffmann-La Roche Ltd
    • 6.1.7 Incyte Corp
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 Seattle Genetics, Inc.
    • 6.1.10 Teva Pharmaceutical Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top